Picture: Crescendo Biologics

Theodora Harold appointed CEO of Crescendo Biologics

Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Theodora Harold, the current CFO, will be appointed as CEO. She will be succeeding Peter Pack who will be stepping down from the position of CEO on 1 May 2019.

Theodora joined Crescendo in October 2016 and has worked in close partnership with Peter in the day-to-day running of the company ever since. She was central to the recent $70 million fund raising and has had responsibility not only for finance and operations but also, more recently, for business development.

Before joining the company, she held both industry and corporate finance roles with private and listed biotech SMEs including PsiOxus Therapeutics Ltd, MISSION Therapeutics Ltd, OrthoMimetics Ltd and Cytomyx Holdings plc. Prior to this, Theodora qualified as a Chartered Accountant with PricewaterhouseCoopers and read Classics at Trinity College, Cambridge.

Peter Pack remains in his executive position until 1 May 2019 to allow for an orderly succession between him and Theodora, and with the company. He will continue to support Crescendo as a senior advisor.